RT Journal Article
SR Electronic
T1 Development and Content Validation of the Symptoms Evolution of COVID-19: A Patient-Reported Electronic Daily Diary in Clinical and Real-World Studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.06.21259654
DO 10.1101/2021.07.06.21259654
A1 Rofail, Diana
A1 McGale, Nadine
A1 Im, Joseph
A1 Rams, Alissa
A1 Przydzial, Krystian
A1 Mastey, Vera
A1 Sivapalasingam, Sumathi
A1 Podolanczuk, Anna J.
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.06.21259654.abstract
AB Importance At the onset of the COVID-19 pandemic, there was limited understanding of symptom experience and disease progression.Objective We developed and validated a fit-for-purpose, disease-specific instrument to assess symptoms in patients with COVID-19 to inform endpoints in an interventional trial for non-hospitalized patients.Design The initial drafting of the 23-item Symptoms Evolution of COVID-19 (SE-C19) Instrument was developed based on the Centers for Disease Control and Prevention symptom list and available published literature specific to patients with COVID-19 as of Spring 2020. The measurement principles in the Food and Drug Administration patient-reported outcomes guidance and the four methodological Patient-Focused Drug Development Guidances were also considered.Setting Interviews were conducted virtually with patients recruited through a healthcare research firm.Participants Semi-structured qualitative interviews were conducted with a purposive sample of 30 non-hospitalized patients with COVID-19Intervention Interviews involved two stages: (1) concept elicitation, to obtain information about the symptoms experienced as a result of COVID-19 in patients’ own words, and (2) cognitive debriefing, for patients to describe their understanding of the SE-C19 instructions, specific symptoms, response options, and recall period to ensure the content of the SE-C19 is relevant and comprehensive. Five clinicians treating COVID-19 outpatients were interviewed to obtain their insights on symptoms experienced by patients and provide input on the SE-C19.Main Outcome and Measure Patients reported no issues regarding the relevance or appropriateness of the SE-C19 instructions, including the recall period. The comprehensiveness of the SE-C19 was confirmed against the conceptual model developed in the qualitative research. Minor conceptual gaps were revealed to capture nuances in the experience of nasal and gustatory symptoms, and systemic manifestations of sickness.Almost all items were endorsed by patients as being appropriate and well understood. The clinicians largely approved all items, response options, and recall period.Conclusions and Relevance The qualitative research provided supportive evidence of the content validity of the SE-C19 instrument to assess the symptoms of outpatients with COVID-19 and its use in clinical trials to evaluate the benefit of treatment. Minor changes may be considered to improve conceptual clarity and ease of responding.Trial Registration R10933-10987-COV-2067 (https://clinicaltrials.gov/ct2/show/NCT04425629)Competing Interest StatementDR is a Regeneron Pharmaceuticals, Inc. employee/stockholder and former Roche employee, and current stockholder. JI, SS, and VM are Regeneron Pharmaceuticals, Inc. employees/stockholders. AP has received consulting fees from Regeneron Pharmaceuticals, Inc., honoraria from NACE (CME), and has participated in an advisory board for Boehringer Ingelheim. NM, AR, and KP are employees of Modus Outcomes. NM, AR, and KP consulted for Regeneron Pharmaceuticals, Inc.Clinical TrialNCT04425629Funding StatementThis research was sponsored and paid for by Regeneron Pharmaceuticals, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study documents, including the protocol, demographic and health information form, interview guide, screener, informed consent form, and SE-C19, received ethical approval from the New England Independent Review Board (study number: 1291666) prior to any contact with patients. All patients completed an electronic informed consent form before the interview.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable.